232 related articles for article (PubMed ID: 19959081)
1. Epidemiology of chronic myeloid leukaemia (CML).
Rohrbacher M; Hasford J
Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
[TBL] [Abstract][Full Text] [Related]
2. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
3. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Kantarjian HM; Cortes J; Guilhot F; Hochhaus A; Baccarani M; Lokey L
Cancer; 2007 Apr; 109(7):1365-75. PubMed ID: 17326047
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of chronic myeloid leukaemia: an update.
Höglund M; Sandin F; Simonsson B
Ann Hematol; 2015 Apr; 94 Suppl 2():S241-7. PubMed ID: 25814090
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia with typical clinical and morphological features can be Philadelphia chromosome negative and "bcr negative".
Selleri L; Emilia G; Luppi M; Temperani P; Zucchini P; Tagliafico E; Artusi T; Sarti M; Donelli A; Castoldi GL
Hematol Pathol; 1990; 4(2):67-77. PubMed ID: 2197265
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukemia: an overview.
Tennant L
Clin J Oncol Nurs; 2001; 5(5):218-9. PubMed ID: 11899767
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic.
Krol L; Formankova R; Keslova P; Vavra V; Zemanova Z; Michalova K; Dobrovolna M; Moravcova J; Kobylka P; Ivaskova E; Navratilova J; Stary J; Sedlacek P
Neoplasma; 2008; 55(2):101-6. PubMed ID: 18237247
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.
Rohrbacher M; Berger U; Hochhaus A; Metzgeroth G; Adam K; Lahaye T; Saussele S; Müller MC; Hasford J; Heimpel H; Hehlmann R
Leukemia; 2009 Mar; 23(3):602-4. PubMed ID: 18784744
[No Abstract] [Full Text] [Related]
11. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
12. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
13. [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
Nadav L; Eldor A
Harefuah; 2002 Feb; 141(2):158-62, 222. PubMed ID: 11905088
[TBL] [Abstract][Full Text] [Related]
14. Flying under the radar: the new wave of BCR-ABL inhibitors.
Quintás-Cardama A; Kantarjian H; Cortes J
Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
[TBL] [Abstract][Full Text] [Related]
15. Glivec and CML: a lucky date.
Saglio G; Cilloni D; Rancati F; Boano L
J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
17. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
18. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients.
Tardieu S; Brun-Strang C; Berthaud P; Michallet M; Guilhot F; Rousselot P; Sambuc R
Pharmacoepidemiol Drug Saf; 2005 Aug; 14(8):545-53. PubMed ID: 15534856
[TBL] [Abstract][Full Text] [Related]
19. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
20. [Clinical epidemiology].
Ohyashiki K
Nihon Rinsho; 2001 Dec; 59(12):2416-20. PubMed ID: 11766349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
